Moreover, analysis in cancers that are frequently mutated for KRAS also demonstrates an upregulated expression of ACOX2 mRNA in KRAS-mutated colon adenocarcinoma (Figure 5E) or rectal adenocarcinoma (Figure 5F), with the exception of pancreatic adenocarcinoma, where ACOX2 expression was decreased as a consequence of KRAS mutation (Figure 5D). This evidence concerns the gene KRAS and pancreatic adenocarcinoma.